Elon Musk Backs Multiple BCI Approaches

Musk backing Synchron showed that the early BCI market was not shaping up as a winner take all race around one implant design. Synchron was already proving a very different path to market, using a stent like device placed through blood vessels, standard cath lab workflows, and shorter hospital stays, while Neuralink pursued higher signal quality through open skull surgery and custom robotics. That made it rational to back both technical paths before the market revealed which tradeoff patients, doctors, and regulators would favor.

• Synchrons December 2022 $75 million Series C brought in ARCH, Gates Frontier, Bezos Expeditions, Reliance Digital Health, and other investors. The syndicate itself signaled that major backers saw room for multiple BCI architectures, not just one dominant design.
  1 sacra 2 sacra 3 businesswire
• The practical difference is in the procedure. Synchrons Stentrode is threaded through the jugular vein and deployed near motor cortex using catheter tools many hospitals already have. Neuralink requires a craniotomy and a specialized robot, but in exchange can capture denser signals and stronger cursor control.
  2 sacra
• Musks interest in Synchron started before the round closed. Reuters reported in August 2022 that he approached Synchron about a potential investment, while later reporting tied that interest to Neuralinks slower progress at the time. The investment looks less like a side bet and more like strategic hedging across the main technical approaches.
  6 cnbc 7 cnbc

Going forward, the market is likely to split by use case. Less invasive systems should win first where hospitals need simpler procedures and safer adoption, while higher bandwidth implants should lead where performance matters most. Capital will keep flowing to both, because BCI is becoming a race between clinical convenience and signal quality, not a race with only one viable model.